Wastewater treatment plants (WWTPs) are regarded as the
main sources
of estrogens that reach the aquatic environment. Hence, continuous
monitoring of potential estrogenic-active compounds by a biosensor
is an appealing approach. However, existing biosensors cannot simultaneously
distinguish and quantify estrogenic agonists and antagonists. To overcome
the challenge, we developed an estrogen receptor-based biosensor that
selectively screened estrogenic agonists and antagonists by introducing
rationally designed agonist/antagonist conformation-specific reporters.
The double functional conformation-specific reporters consist of a
Cy5.5-labeled streptavidin moiety and a peptide moiety, serving as
signal recognition and signal transduction elements. In addition,
the conformation recognition mechanism was further validated at the
molecular level through molecular docking. Based on the two-step “turn-off”
strategy, the biosensor exhibited remarkable sensitivity, detecting
17β-estradiol-binding activity equivalent (E2-BAE)
at 7 ng/L and 4-hydroxytamoxifen-binding activity equivalent (4-OHT-BAE)
at 91 ng/L. To validate its practicality, the biosensor was employed
in a case study involving wastewater samples from two full-scale WWTPs
across different treatment stages to map their estrogenic agonist
and antagonist binding activities. Comparison with the yeast two-hybrid
bioassay showed a strong liner relationship (r
2 = 0.991, p < 0.0001), indicating the
excellent accuracy and reliability of this technology in real applications.